These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 14993256)

  • 41. Self-vaccination by methamphetamine glycation products chemically links chronic drug abuse and cardiovascular disease.
    Treweek J; Wee S; Koob GF; Dickerson TJ; Janda KD
    Proc Natl Acad Sci U S A; 2007 Jul; 104(28):11580-4. PubMed ID: 17592122
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment of methamphetamine abuse: an antibody-based immunotherapy approach.
    Chen YH; Wu KL; Tsai HM; Chen CH
    J Food Drug Anal; 2013 Dec; 21(4):S82-S86. PubMed ID: 26334109
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The fate and function of therapeutic antiaddiction monoclonal antibodies across the reproductive cycle of rats.
    Hubbard JJ; Laurenzana EM; Williams DK; Gentry WB; Owens SM
    J Pharmacol Exp Ther; 2011 Feb; 336(2):414-22. PubMed ID: 20962030
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The development of antibody-based immunotherapy for methamphetamine abuse: immunization, and virus-mediated gene transfer approaches.
    Chen YH; Chen CH
    Curr Gene Ther; 2013 Feb; 13(1):39-50. PubMed ID: 23157545
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Methamphetamine self-administration by humans.
    Hart CL; Ward AS; Haney M; Foltin RW; Fischman MW
    Psychopharmacology (Berl); 2001 Aug; 157(1):75-81. PubMed ID: 11512046
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Anti-(+)-methamphetamine monoclonal antibody antagonists designed to prevent the progression of human diseases of addiction.
    Gentry WB; Rüedi-Bettschen D; Owens SM
    Clin Pharmacol Ther; 2010 Sep; 88(3):390-3. PubMed ID: 20668443
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Monoclonal antibodies as pharmacokinetic antagonists for the treatment of (+)-methamphetamine addiction.
    Owens SM; Atchley WT; Hambuchen MD; Peterson EC; Gentry WB
    CNS Neurol Disord Drug Targets; 2011 Dec; 10(8):892-8. PubMed ID: 22229314
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Speed kills: fatality from the self-administration of methamphetamine intravenously.
    Hall CD; Blanton DE; Scatliff JH; Morris CE
    South Med J; 1973 Jun; 66(6):650-2. PubMed ID: 4708566
    [No Abstract]   [Full Text] [Related]  

  • 49. [Forensic immunochemical studies of methamphetamine--preparation of a specific antibody to methamphetamine].
    Iwasaki M
    Nihon Hoigaku Zasshi; 1987 Jun; 41(3):217-23. PubMed ID: 3316754
    [No Abstract]   [Full Text] [Related]  

  • 50. Correction: The Anti-(+)-Methamphetamine Monoclonal Antibody mAb7F9 Attenuates Acute (+)-Methamphetamine Effects on Intracranial Self-Stimulation in Rats.
    Harris AC; LeSage MG; Shelley D; Perry JL; Pentel PR; Owens SM
    PLoS One; 2015; 10(9):e0138959. PubMed ID: 26383646
    [No Abstract]   [Full Text] [Related]  

  • 51. The rate of localization of anti-rat kidney antibodies.
    BLAU M; DAY ED; PRESSMAN D
    J Immunol; 1957 Oct; 79(4):330-3. PubMed ID: 13481383
    [No Abstract]   [Full Text] [Related]  

  • 52. Look, nurse; no crank!
    JAMES EE
    Mod Hosp; 1956 Dec; 87(6):128; passim. PubMed ID: 13378311
    [No Abstract]   [Full Text] [Related]  

  • 53. Medications Discovery: Importance of Assessment of Drug Self Administration Dose-Effect Curves.
    Hiranita T
    J Alcohol Drug Depend; 2015 Jun; 3(3):. PubMed ID: 27413771
    [No Abstract]   [Full Text] [Related]  

  • 54. Immunotherapies for the Treatment of Drug Addiction.
    Hossain MK; Davidson M; Kypreos E; Feehan J; Muir JA; Nurgali K; Apostolopoulos V
    Vaccines (Basel); 2022 Oct; 10(11):. PubMed ID: 36366287
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Active and Passive Immunization with an Anti-Methamphetamine Vaccine Attenuates the Behavioral and Cardiovascular Effects of Methamphetamine.
    Haile CN; Varner KJ; Huijing X; Arora R; Orson FM; Kosten TR; Kosten TA
    Vaccines (Basel); 2022 Sep; 10(9):. PubMed ID: 36146588
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunopharmacotherapeutic advancements in addressing methamphetamine abuse.
    Lee JC; Janda KD
    RSC Chem Biol; 2021 Feb; 2(1):77-93. PubMed ID: 34458776
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of a methamphetamine vaccine, IXT-v100, on methamphetamine-related behaviors.
    Keller CM; Spence AL; Stevens MW; Owens SM; Guerin GF; Goeders NE
    Psychopharmacology (Berl); 2020 Mar; 237(3):655-667. PubMed ID: 31758209
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Development and testing of AAV-delivered single-chain variable fragments for the treatment of methamphetamine abuse.
    Hay CE; Gonzalez GA; Ewing LE; Reichard EE; Hambuchen MD; Nanaware-Kharade N; Alam S; Bolden CT; Owens SM; Margaritis P; Peterson EC
    PLoS One; 2018; 13(6):e0200060. PubMed ID: 29958300
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Conjugate Vaccine Immunotherapy for Substance Use Disorder.
    Bremer PT; Janda KD
    Pharmacol Rev; 2017 Jul; 69(3):298-315. PubMed ID: 28634286
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Recombinant Adeno-Associated Virus-Mediated Expression of Methamphetamine Antibody Attenuates Methamphetamine-Induced Hyperactivity in Mice.
    Chen YH; Wu KJ; Wu KL; Wu KL; Tsai HM; Chen ML; Chen YW; Hsieh W; Lin CM; Wang Y
    Sci Rep; 2017 Apr; 7():46301. PubMed ID: 28387350
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.